[go: up one dir, main page]

MA56283A1 - Compositions immunogènes contre des maladies entériques et leurs procédés de préparation - Google Patents

Compositions immunogènes contre des maladies entériques et leurs procédés de préparation

Info

Publication number
MA56283A1
MA56283A1 MA56283A MA56283A MA56283A1 MA 56283 A1 MA56283 A1 MA 56283A1 MA 56283 A MA56283 A MA 56283A MA 56283 A MA56283 A MA 56283A MA 56283 A1 MA56283 A1 MA 56283A1
Authority
MA
Morocco
Prior art keywords
polysaccharide
typhi
methods
immunogenic compositions
preparation
Prior art date
Application number
MA56283A
Other languages
English (en)
Inventor
Rajeev Mhalasakant Dhere
Sambhaji Shankar Pisal
Dattatreya Sarma Annamraju
Nikhil Dattatray Avalaskar
Yogesh Tukaram Hundekari
Anil Pirajirao Taklikar
Sunil Kumar Goel
Chandrashekhar Dwarkanath Kamat
Vishal Bharat Chavan
Original Assignee
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd filed Critical Serum Institute Of India Pvt Ltd
Publication of MA56283A1 publication Critical patent/MA56283A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouvelles compositions immunogènes de vaccin conjugué polysaccharide-protéine monovalentes et multivalentes comprenant un polysaccharide choisi parmi des souches de salmonella serovar ; s. Typhi ; s. Paratyphi a ; s. Typhimurium et s. Enteritidis et d'autres procédés améliorés de fermentation de polysaccharide, de purification de polysaccharide, de conjugaison polysaccharide-protéine et de formulation stable. La présente invention concerne en outre des méthodes pour induire une réponse immunitaire chez des sujets contre salmonella typhi et des maladies associées non typhi et/ou pour réduire ou prévenir salmonella typhi et des maladies associées non typhi chez des sujets à l'aide des compositions selon l'invention. Le vaccin déclenche des anticorps bactéricides et est utile pour la prévention de la gastroentérite, de la fièvre entérique et typhoïde.
MA56283A 2019-09-03 2020-09-02 Compositions immunogènes contre des maladies entériques et leurs procédés de préparation MA56283A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921035435 2019-09-03
PCT/IN2020/050763 WO2021044436A2 (fr) 2019-09-03 2020-09-02 Compositions immunogènes contre des maladies entériques et leurs procédés de préparation

Publications (1)

Publication Number Publication Date
MA56283A1 true MA56283A1 (fr) 2023-01-31

Family

ID=72659843

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56283A MA56283A1 (fr) 2019-09-03 2020-09-02 Compositions immunogènes contre des maladies entériques et leurs procédés de préparation

Country Status (22)

Country Link
US (2) US20230149524A1 (fr)
EP (2) EP4025246A2 (fr)
JP (2) JP7732974B2 (fr)
KR (2) KR20220087437A (fr)
CN (1) CN114728053A (fr)
AR (1) AR119884A1 (fr)
AU (1) AU2020343943A1 (fr)
BR (1) BR112022003892A2 (fr)
CA (1) CA3149972A1 (fr)
CO (1) CO2022003789A2 (fr)
CR (1) CR20220132A (fr)
EC (1) ECSP22031077A (fr)
GB (2) GB2629746B (fr)
GE (2) GEAP202515919A (fr)
IL (1) IL291006B1 (fr)
JO (1) JOP20200214A1 (fr)
MA (1) MA56283A1 (fr)
MX (1) MX2022002693A (fr)
PE (1) PE20221442A1 (fr)
PH (1) PH12022550525A1 (fr)
WO (1) WO2021044436A2 (fr)
ZA (1) ZA202203368B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025021712A1 (fr) * 2023-07-21 2025-01-30 Glaxosmithkline Biologicals Sa Composition immunogène

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
AU1420897A (en) * 1996-12-18 1998-07-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Conjugate vaccine for (salmonella paratyphi) a
CN1263510C (zh) 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
KR101408113B1 (ko) 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
RU2518289C2 (ru) 2006-09-13 2014-06-10 Эббви Инк, Способ получения антитела или его фрагмента с подпиткой (варианты)
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
FR2938265B1 (fr) 2008-11-12 2011-07-15 Univ Claude Bernard Lyon Procede pour le pilotage d'un traitement de depolymerisation par ultrasons d'un biopolymere hydrosoluble
KR101605171B1 (ko) * 2009-12-17 2016-03-21 피나 바이오솔루션스, 엘엘씨 접합 백신 제조시 다당류를 활성화시키기 위한 화학 시약
US9011871B2 (en) * 2011-11-07 2015-04-21 University Of Maryland, Baltimore Broad spectrum vaccine against typhoidal and non-typhoidal Salmonella disease
IN2012MU00206A (fr) * 2012-01-20 2013-08-09
MX354103B (es) 2012-01-30 2018-02-13 Serum Inst India Ltd Composicion inmunogenica.
CN102935226B (zh) * 2012-11-16 2014-01-22 罗益（无锡）生物制药有限公司 伤寒甲型副伤寒结合疫苗及其制备方法
EP3329935B1 (fr) * 2013-08-24 2025-01-08 Bharat Biotech International Limited Vaccin bactérien et procédés de fabrication
CN104383532A (zh) * 2014-12-02 2015-03-04 云南沃森生物技术股份有限公司 一种用乙肝表面抗原为载体蛋白的细菌多糖蛋白结合物疫苗及其制备方法
CN104587461A (zh) * 2015-01-05 2015-05-06 云南沃森生物技术股份有限公司 伤寒、甲型乙型副伤寒多糖蛋白结合型多价联合疫苗
WO2017006349A1 (fr) * 2015-07-04 2017-01-12 Bharat Biotech International Limited Formulations vaccinales à base de polysaccharides et procédés de production industrielle de polysaccharides bactériens
WO2017187448A1 (fr) * 2016-04-25 2017-11-02 National Institute Of Immunology Nouveau conjugué pour vaccination contre la typhoïde comprenant un conjugué chimique de polysaccharide vi et de flagelline, son procédé de production et composition comprenant le conjugué
PH12019500404B1 (en) 2016-08-26 2024-05-15 Serum Institute Of India Pvt Ltd Multivalent vaccine composition
MY202666A (en) * 2017-05-05 2024-05-14 Serum Institute Of India Pvt Ltd Method for removal of impurities from bacterial capsular polysaccharide based preparations
CA3070039A1 (fr) 2017-07-18 2019-01-24 Serum Institute Of India Pvt Ltd. Composition immunogene a stabilite amelioree, immunogenicite amelioree et moindre reactogenicite, et procede de preparation de cette derniere
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
MX2021005500A (es) * 2018-11-10 2021-09-08 Bharat Biotech Int Ltd Composiciones inmunogenicas de glicoconjugados multivalentes.

Also Published As

Publication number Publication date
CN114728053A (zh) 2022-07-08
KR20220087437A (ko) 2022-06-24
GB2603362A (en) 2022-08-03
EP4249061A2 (fr) 2023-09-27
US20250134980A1 (en) 2025-05-01
JP7732974B2 (ja) 2025-09-02
IL291006A (en) 2022-05-01
MX2022002693A (es) 2022-07-12
EP4025246A2 (fr) 2022-07-13
JP2022546763A (ja) 2022-11-08
GEAP202515919A (en) 2025-05-27
AU2020343943A1 (en) 2022-03-24
WO2021044436A3 (fr) 2021-05-27
BR112022003892A2 (pt) 2022-05-24
CO2022003789A2 (es) 2022-04-19
IL291006B1 (en) 2025-11-01
EP4249061A3 (fr) 2023-11-15
US20230149524A1 (en) 2023-05-18
CA3149972A1 (fr) 2021-03-11
JOP20200214A1 (ar) 2021-03-03
KR20240155975A (ko) 2024-10-29
ZA202203368B (en) 2022-05-25
CR20220132A (es) 2022-05-06
GB2603362B (en) 2025-01-15
GB2629746B (en) 2025-01-29
AR119884A1 (es) 2022-01-19
GEP20257808B (en) 2025-10-27
JP2024178271A (ja) 2024-12-24
GB202204276D0 (en) 2022-05-11
PE20221442A1 (es) 2022-09-21
ECSP22031077A (es) 2022-05-31
PH12022550525A1 (en) 2023-03-20
GB2629746A (en) 2024-11-06
WO2021044436A2 (fr) 2021-03-11

Similar Documents

Publication Publication Date Title
MA51048B1 (fr) Compositions comprenant des conjugues de polysaccharide-proteine de streptococcus pneumoniae et leurs procedes d'utilisation
US7862823B1 (en) Multivalent vaccine composition with mixed carrier
HU229968B1 (hu) Sztreptokokkusz oltóanyag
JPH06510530A (ja) 大腸菌　ｏ−多糖−タンパク質結合ワクチン
JP6998866B2 (ja) 緑膿菌ＰｃｒＶ連結型抗原ワクチン
JP2004512269A5 (fr)
BE1025443B1 (fr) CONJUGUES nOMV-ANTIGENE ET LEUR UTILISATION
TW200823230A (en) Protein matrix vaccines and methods of making and administering such vaccines
RU2006114677A (ru) Жидкие вакцины для множественных серогрупп менингококков
BR0310062A (pt) Vacinas mucosas com adjuvante de quitosana e/ou antìgenos meningocócicos
TW200815028A (en) Conjugation process
FR2806304A1 (fr) Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
Xu et al. Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein
MA56283A1 (fr) Compositions immunogènes contre des maladies entériques et leurs procédés de préparation
DE69936296D1 (de) Konjugat-impfstoffe zur vorbeugung der zahnkaries
JP2020525495A (ja) 新規の多価多糖類・タンパク質のコンジュゲートワクチン組成物及びその製剤
FR2717081B1 (fr) Rétropeptides, anticorps dirigés contre ces derniers, et leurs utilisations pour la vaccination et le diagnostic in vitro.
BE1021934B1 (fr) Procede de traitement
US20210401960A1 (en) Multivalent glycoconjugates immunogenic compositions
US20030068324A1 (en) Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid
CA2761924C (fr) Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6
Yan et al. Polysaccharide-conjugate vaccines for Burkholderia pseudomallei based on the O-antigens of serotypes A and B.
ZA202402956B (en) Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
MX2024004116A (es) Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y formulacion de vacuna multivalente obtenida de los mismos